AR119031A1 - Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de utilización de la misma - Google Patents
Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de utilización de la mismaInfo
- Publication number
- AR119031A1 AR119031A1 ARP200101510A ARP200101510A AR119031A1 AR 119031 A1 AR119031 A1 AR 119031A1 AR P200101510 A ARP200101510 A AR P200101510A AR P200101510 A ARP200101510 A AR P200101510A AR 119031 A1 AR119031 A1 AR 119031A1
- Authority
- AR
- Argentina
- Prior art keywords
- lysozyme
- infections
- methods
- formulation
- spectrum antibacterial
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 230000000844 anti-bacterial effect Effects 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000016943 Muramidase Human genes 0.000 abstract 4
- 108010014251 Muramidase Proteins 0.000 abstract 4
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 abstract 4
- 229960000274 lysozyme Drugs 0.000 abstract 4
- 235000010335 lysozyme Nutrition 0.000 abstract 4
- 239000004325 lysozyme Substances 0.000 abstract 4
- 208000035143 Bacterial infection Diseases 0.000 abstract 3
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 3
- 208000036142 Viral infection Diseases 0.000 abstract 2
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 230000009385 viral infection Effects 0.000 abstract 2
- 208000025721 COVID-19 Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010057190 Respiratory tract infections Diseases 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 230000009291 secondary effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Otolaryngology (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962853215P | 2019-05-28 | 2019-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR119031A1 true AR119031A1 (es) | 2021-11-17 |
Family
ID=73551002
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP200101510A AR119031A1 (es) | 2019-05-28 | 2020-05-28 | Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de utilización de la misma |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20200376094A1 (https=) |
| EP (1) | EP3976093A4 (https=) |
| JP (3) | JP7768769B2 (https=) |
| CN (1) | CN114126643A (https=) |
| AR (1) | AR119031A1 (https=) |
| BR (1) | BR112021024001A2 (https=) |
| CA (1) | CA3145530A1 (https=) |
| CO (1) | CO2021017958A2 (https=) |
| IL (1) | IL288531A (https=) |
| MX (1) | MX2021014634A (https=) |
| TW (1) | TW202110474A (https=) |
| WO (1) | WO2020240472A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3928785B1 (en) * | 2020-04-27 | 2024-07-31 | Guangzhou Century Clinical Research Co., Ltd | Medicament and food for use in preventing or treating novel coronavirus pneumonia covid-19 |
| EP4144363A4 (en) * | 2020-04-27 | 2024-05-29 | Guangzhou Century Clinical Research Co., Ltd | Drug, food and application of anti-coronavirus infection |
| WO2023133412A2 (en) * | 2022-01-05 | 2023-07-13 | Prophase Labs, Inc. | Compositions having synergistic anti-viral action and methods for treating coronavirus |
| CN114503981A (zh) * | 2022-01-07 | 2022-05-17 | 上海膜益信息科技有限公司 | 一种不分层防霉液及其制备方法和应用 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK501686A (da) * | 1986-10-20 | 1988-04-21 | Otto Melchior Poulsen | Enzymholdigt, baktericidt middel samt tandplejemidler og saarbehandlingsmidler, som indeholder det |
| CN1557485A (zh) * | 2004-01-30 | 2004-12-29 | 大连帝恩生物工程有限公司 | 基因重组人溶菌酶在消除病原微生物感染炎症上的应用 |
| CA2561876C (en) * | 2004-04-08 | 2013-01-08 | Kenneth Vincent Mason | Antimicrobial compositions and methods for their use |
| CN1583170A (zh) * | 2004-06-10 | 2005-02-23 | 安米 | 用于抗病毒抗耐药菌的人溶菌酶药物及其制法 |
| US20080095754A1 (en) * | 2006-10-18 | 2008-04-24 | Burke Susan E | Ophthalmic compositions comprising diglycine |
| WO2009051838A1 (en) * | 2007-10-19 | 2009-04-23 | Becton Dickinson And Company | Methods and compositions for the detection of beta-lactamases |
| EP2349209A2 (en) * | 2008-09-26 | 2011-08-03 | Nanobio Corporation | Nanoemulsion therapeutic compositions and methods of using the same |
| UA48016U (ru) * | 2010-01-25 | 2010-02-25 | Илона Васильевна Ковач | Способ профилактики кариеса зубов у детей 3-6 лет |
| UA68612U (ru) * | 2012-02-07 | 2012-03-26 | Дмитрий Викторович Дудар | Способ лечения хронического рецидивирующего афтозного стоматита у больных целиакией |
| CA2905788C (en) * | 2013-03-12 | 2022-08-16 | Emily A. Stein | Dental composition comprising chelator and base |
| CN110352237B (zh) * | 2017-02-28 | 2023-01-10 | 精密生物集团有限公司 | 可以有益地调节针对呼吸道病毒感染的免疫应答的长双歧杆菌 |
| EP3655020A4 (en) * | 2017-07-17 | 2021-04-07 | The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Antibacterial methods and related kits |
| CN107899006A (zh) * | 2017-11-28 | 2018-04-13 | 四川清舒乐科技有限公司 | 冲洗鼻腔的药物组合物及其制备方法 |
-
2020
- 2020-05-28 EP EP20815355.1A patent/EP3976093A4/en not_active Withdrawn
- 2020-05-28 BR BR112021024001A patent/BR112021024001A2/pt unknown
- 2020-05-28 MX MX2021014634A patent/MX2021014634A/es unknown
- 2020-05-28 JP JP2021571513A patent/JP7768769B2/ja active Active
- 2020-05-28 AR ARP200101510A patent/AR119031A1/es unknown
- 2020-05-28 WO PCT/IB2020/055083 patent/WO2020240472A1/en not_active Ceased
- 2020-05-28 US US16/885,537 patent/US20200376094A1/en not_active Abandoned
- 2020-05-28 CN CN202080048142.9A patent/CN114126643A/zh active Pending
- 2020-05-28 CA CA3145530A patent/CA3145530A1/en active Pending
- 2020-05-28 TW TW109117916A patent/TW202110474A/zh unknown
-
2021
- 2021-11-29 IL IL288531A patent/IL288531A/en unknown
- 2021-12-28 CO CONC2021/0017958A patent/CO2021017958A2/es unknown
-
2022
- 2022-07-28 US US17/875,872 patent/US20220362354A1/en not_active Abandoned
-
2023
- 2023-11-09 US US18/505,472 patent/US20240066105A1/en active Pending
-
2024
- 2024-12-10 JP JP2024215483A patent/JP2025038034A/ja active Pending
-
2025
- 2025-10-30 JP JP2025183379A patent/JP2026021451A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3145530A1 (en) | 2020-12-03 |
| CN114126643A (zh) | 2022-03-01 |
| CO2021017958A2 (es) | 2022-01-17 |
| JP2022534776A (ja) | 2022-08-03 |
| JP7768769B2 (ja) | 2025-11-12 |
| IL288531A (en) | 2022-01-01 |
| WO2020240472A1 (en) | 2020-12-03 |
| US20240066105A1 (en) | 2024-02-29 |
| US20220362354A1 (en) | 2022-11-17 |
| US20200376094A1 (en) | 2020-12-03 |
| EP3976093A1 (en) | 2022-04-06 |
| EP3976093A4 (en) | 2023-07-05 |
| TW202110474A (zh) | 2021-03-16 |
| BR112021024001A2 (pt) | 2022-01-25 |
| JP2026021451A (ja) | 2026-02-10 |
| JP2025038034A (ja) | 2025-03-18 |
| MX2021014634A (es) | 2022-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021017958A2 (es) | Formulaciones farmacéuticas antibacterianas de amplio espectro que comprenden lisozima y métodos de uso de las mismas | |
| JP2020527134A5 (https=) | ||
| CN108853312B (zh) | 聚桂醇外用凝胶及其制备方法 | |
| CA2474479A1 (en) | Composition for inhalation | |
| CY1110376T1 (el) | Χρηση μιας συνθεσης που περιλαμβανει φορμοτερολη και βουδεσονιδη για την προληψη απο ή τη θεραπευτικη αντιμετωπιση μιας οξειας καταστασης ασθματος | |
| MX2021014161A (es) | Metodos de tratamiento del sindrome de sjogren utilizando un inhibidor de la tirosina quinasa de bruton. | |
| WO2020076760A3 (en) | Sphingoid compounds for use in the prophylaxis and/or therapy of a viral infection | |
| CO2022016153A2 (es) | Inhibidores de il4i1 y métodos de uso | |
| HK1243354B (zh) | 新颖碘伏组合物及其使用方法 | |
| AR052047A1 (es) | Metodos de uso y composiciones comprendiendo moduladores de pde4 para el tratamiento prevencion y control de inflamacion de las vias respiratorias | |
| CL2024003601A1 (es) | Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas. | |
| EA201992759A1 (ru) | Ассоциация, включающая кислород и гиалуроновую кислоту, для местного вагинального применения | |
| MX2022003845A (es) | Tratamientos cognitivos medicinales. | |
| BR112012020185A2 (pt) | uso de preparações de heparina oral para tratar doenças e afecções do trato urinário. | |
| AR045070A1 (es) | Preparados farmaceuticos topicos de acido ascorbico con efecto post-antimicotico | |
| MX2023013226A (es) | Métodos para tratar, mejorar o prevenir infecciones mediante un tratamiento combinado de farmacos y vacunación. | |
| AR036009A1 (es) | Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica | |
| Wang et al. | Tissue injury by hot fluid containing nitrogen mustard | |
| EA202192234A1 (ru) | Комбинированная терапия для применения в лечении рака | |
| MX2021016090A (es) | Lemborexant para el tratamiento de problemas del sueño. | |
| KR20200075335A (ko) | 피부병 치료제 | |
| PH12022551384A1 (en) | Chronic wound healing composition and application thereof | |
| Natarajan et al. | Facial dog bite injury | |
| GEAP202215586A (en) | Therapy of high-risk human papillomavirus infections | |
| MX2025005174A (es) | Formulacion oral de derivado de n-piridinilacetamida para tratar la enfermedad pulmonar intersticial |